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S2
Results for the four 4 × 2 × 8 libraries using an automated synthesizer (Scheme 5) Purity was determined by reverse-phase HPLC (Waters Acquity system) with peak area (UV) at 214 nm. (Waters Acquity BEH C-18 column, 2.1 × 50 mm, 1.7 μm elution with a linear gradient of 5% acetonitrile in pH 9.8 buffered aqueous ammonium formate to 100% acetonitrile at 0.6 mL·min −1 flow rate)
S7

Full characterization data for representative compounds
General information: Full compound characterizations for a representative set of 20 γ-lactams resulting from the four 4 × 2 × 8 libraries shown in Scheme 5 in the main manuscript are reported. 7, 169.5, 157.1, 138.5, 131.8, 128.8, 123.8, 122.2, 119.7, 114.2, 55.5, 54.8, 48.1, 38.2, 34.1, 16.7; MS (ESI) 169.3, 137.7, 137.5, 132.0, 131.8, 121.6, 121.2, 118.1, 116.3, 54.2, 48.1, 41.0, 37.8, 33.8, 16.6 1, 169.3, 138.5, 138.4, 135.7, 128.8, 128.8, 128.7, 128.7, 127.9, 127.8, 126.6, 123.8, 119.7, 50.5, 46.8, 45.3, 40.3, 38.7, 38 169.0, 149.4, 149.3, 138.3, 138.2, 135.7, 131.5, 128.9, 128.8, 128.7, 126.8, 124.0, 123.8, 119.6, S10 50.6, 45.1, 44.4, 40.3, 38.7, 38.0 138.5, 131.9, 128.8, 123.8, 122.3, 119.7, 114.2, 55.5, 53.6, 46.8, 38.6, 38.6, 34.9, 20.5, 14 5, 171.9, 156.9, 132.1, 122.0, 114.1, 55.5, 53.4, 46.8, 38.3, 37.0, 35.0, 26.3, 20.4, 14 1, 169.9, 155.9, 139.2, 131.9, 129.0, 128.7, 128.7, 126.6, 121.4, 121.3, 114.0, 114.0, 55.5, 55.5, 50.9, 45.0, 43. 8, 40.9, 38.3, 35.0, 33.7, 30.3, 25.4, 25.3; MS (ESI) = 1.9 Hz, 1H), 7.55 (dt, J = 7.8, 1.9 Hz, 1H), 2H), 2H), 7.25 (ddd, J = 7.8, 4.8, 0.6 Hz, 1H), 4.51 (m, 2H), 1H) 9, 169.4, 149.5, 149.4, 137.7, 135.7, 131.8, 131.4, 123.9, 121.1, 116.2, 51.2, 45.4, 44.5, 38.9, 38.6, 35.0, 20.4, 14.1; MS (ESI) 3, 171.6, 138.3, 128.7, 128.6, 126.7, 51.2, 44.9, 44.2, 38.1, 37.2, 37.0, 33.6, 26.3, 15.9; MS (ESI) 36 (s, 1H), 2H), 3H), J = 5.6, 2.1 Hz, 2H), 2H), 2H), 3.79 (s, 3H), 3.42 (dd, J = 10.1, 8.1 Hz, 1H) 135.6, 131.6, 128.7, 128.0, 127.9, 121.4, 114.0, 55.5, 50.4, 46.9, 45.0, 38.1, 38.0, 37.1, 16.0 169.3, 137.7, 131.7, 121.2, 116.2, 51.0, 44.9, 42.8, 38.8, 38.6, 36.9, 29.2, 20.0, 16.1, 13.7 8, 169.2, 159.3, 157.3, 137.6, 131.8, 131.5, 129.6, 128.8, 122.3, 121.2, 116.2, 114.6, 114.3, 55.5, 55.4, 54.9, 47.9, 44.5, 37.8 1, 138.8, 137.7, 131.7, 129.1, 125.4, 121.2, 120.4, 116.1, 61.0, 51.2, 37.8, 34.7, 24.9, 21.8 
2-((3S,4S)-4-Methyl-2-oxo-1-phenylpyrrolidin-3-yl)-N-phenylacetamide (6{1,1,1}
2-((3S,4S)-1-(4-Methoxyphenyl)-4-methyl-2-oxopyrrolidin-3-yl)-N-phenylacetamide (6{1,1,4}
2-((3S,4S)-1-Benzyl-4-methyl-2-oxopyrrolidin-3-yl)-N-methylacetamide (6{2,1,2}
N-(4-Methoxyphenyl)-2-((3S,4S)-4-methyl-2-oxo-1-phenylpyrrolidin-3-yl)acetamide
N-(4-Bromophenyl)-2-((3S,4S)-1-(4-bromophenyl)-4-methyl-2-oxopyrrolidin-3-
yl)acetamide (6{4,1,5}
2-((3S,4S)-4-Benzyl-2-oxo-1-phenylpyrrolidin-3-yl)-N-phenylacetamide (6{1,3,2}
2-((3S,4S)-4-Benzyl-2-oxo-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl)-N-phenylacetamide (6{1,3,8}
2-((3S
,
2-((3S,4S)-1-Cyclohexyl-4-methyl-2-oxopyrrolidin-3-yl)-N-phenylacetamide (6{3,3,6}).
2-((3S
